MMPIP is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (K_Bvalues 24 -30 nM). MMPIP acts as a pharmacological tool for elucidating the roles ofmGluR7on central nervous system functions. MMPIP alleviates pain and normalizes affective and cognitive behavior in neuropathic mice^[1][2].

MMPIP inhibits L-(+)-2-amino-4-phosphonobutyric acid (L-AP4; 0.5 mM)-induced intracellular Ca²⁺mobilization in Chinese hamster ovary (CHO) cells coexpressing rat mGluR7 with G_α15(IC5₅₀=26 nM)^[1].
In CHO cells expressing rat mGluR7, MMPIP inhibits L-AP4-induced inhibition of forskolin-stimulated cAMP accumulation (IC₅₀220 nM)^[1].
MMPIP also antagonizes L-AP4-induced inhibition of cAMP accumulation with an IC₅₀of 610 nM in CHO-human mGluR7/G_α15^[1].

MMPIP (10 mg/kg) attenuates the amplitude of the acoustic startle response and markedly enhances the prepulse-induced inhibition of the acoustic startle response (up to 137% of control)^[2].
MMPIP (10 mg/kg) rescues the MK-801 (0.1 mg/kg)-induced cognitive impairments, by improving the choice accuracy^[2].
Zamifenacin exhibits short elimination half-lives (plasma 1.16 h, brain 1.75 h) following i.p. administration (10 mg/kg) in mice^[2].

333.34

C₁₉H₁₅N₃O₃

479077-02-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.